Celator Pharmaceuticals (CPXX) VYXEOS Phase 3 in AML Reaches Required Number of Events for OS Analysis
Tweet Send to a Friend
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
